Circulating melanoma cells in the diagnosis and monitoring of melanoma: An appraisal of clinical potential

Molecular Diagnosis and Therapy

Volumn 18, Issue 2, 2014, Pages 175-183

  Mumford, Brigid S ^a   Robertson, Gavin P ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NOTCH RECEPTOR; OSTEONECTIN; SCATTER FACTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VASCULOTROPIN; VIMENTIN; WNT PROTEIN;

APOPTOSIS; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CIRCULATING MELANOMA CELL; CIRCULATING TUMOR CELL; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOCYTOCHEMISTRY; MELANOMA; MELANOMA CELL; METASTASIS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; SURVIVAL TIME;

DISEASE-FREE SURVIVAL; HUMANS; INDIVIDUALIZED MEDICINE; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS;

EID: 84897389572     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0071-2     Document Type: Review

References (76)

1. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253(2):180-204. (Pubitemid 47017533)
2. Seiter S, Rappl G, Tilgen W, Ugurel S, Reinhold U. Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR. Recent Results Cancer Res. 2001;158:105-12.
3. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359(26):2814-23.
4. Huh SJ, Liang S, Sharma A, Dong C, Robertson GP. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010;70(14):6071-82.
5. Nezos A, Msaouel P, Pissimissis N, Lembessis P, Sourla A, Armakolas A, et al. Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev. 2011;37(4):284-90.
6. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 2005;65(14):5991-5 discussion 5.
7. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate. 2006;66(15):1664-73. (Pubitemid 44646357)
8. Rodriguez MI, Peralta-Leal A, O'Valle F, Rodriguez-Vargas JM, Gonzalez-Flores A, Majuelos-Melguizo J, et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet. 2013;9(6):e1003531.
9. Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D, Menke A. TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci. 2005;118(Pt 20):4901-12. (Pubitemid 41646396)
10. Van Den Bossche K, Naeyaert JM, Lambert J. The quest for the mechanism of melanin transfer. Traffic. 2006;7(7):769-78. (Pubitemid 43871769)
11. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98(10):1512-20. (Pubitemid 47308444)
12. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24(50):7443-54. (Pubitemid 41637984)
13. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973-81.
14. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-42. (Pubitemid 43278296)
15. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548-58. (Pubitemid 41267170)
16. Concepcion Garrido M, Requena L, Kutzner H, Ortiz P, Perez-Gomez B, Rodriguez-Peralto JL. Desmoplastic melanoma: expression of epithelial- mesenchymal transition-related proteins. Am J Dermatopathol. 2013. PubMed PMID: 23974224.
17. Hsu MY, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000;156(5):1515-25. (Pubitemid 30646691)
18. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004;48(5-6):365-75. (Pubitemid 39360388)
19. Mazzocca A, Carloni V. The metastatic process: methodological advances and pharmacological challenges. Curr Med Chem. 2009;16(14):1704-17.
20. Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T. E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression. Br J Dermatol. 2013;169(3):618-28.
21. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002;1(3):279-88. (Pubitemid 41039152)
22. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605-12. (Pubitemid 43165918)
23. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell. 2008;135(3):510-23.
24. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res. 2001;61(1):333-8. (Pubitemid 32095735)
25. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst. 1970;45(4):773-82.
26. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274-84.
27. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1(2):149-53.
28. Liotta LA, Kohn E. Anoikis: cancer and the homeless cell. Nature. 2004;430(7003):973-4.
29. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 2005;24(2):273-85. (Pubitemid 40922799)
30. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 2007;67(8):3626-36. (Pubitemid 46762147)
31. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003;63(11):2881-90. (Pubitemid 36667160)
32. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6(6):449-58.
33. Townson JL, Naumov GN, Chambers AF. The role of apoptosis in tumor progression and metastasis. Curr Mol Med. 2003;3(7):631-42. (Pubitemid 37236405)
34. Ireland A, Millward M, Pearce R, Lee M, Ziman M. Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis. 2011;28(4):327-36.
35. Welch DR, Tomasovic SP. Implications of tumor progression on clinical oncology. Clin Exp Metastasis. 1985;3(3):151-88. (Pubitemid 16219653)
36. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA. 2002;99(4):2193-8. (Pubitemid 34169037)
37. Laubli H, Stevenson JL, Varki A, Varki NM, Borsig L. L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest. Cancer Res. 2006;66(3):1536-42. (Pubitemid 43259935)
38. Langley RR, Fidler IJ. The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011;128(11):2527-35.
39. Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res. 2006;66(8):4249-55.
40. Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanger U, Rassner G, Riethmuller G, et al. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res. 2004;10(2):531-7. (Pubitemid 38173991)
41. Ulmer A, Fierlbeck G. Circulating tumor cells and detection of the melanoma-associated antigen HMW-MAA in the serum of melanoma patients. J Invest Dermatol. 2006;126(4):914-5 (author reply 5-6).
42. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369(9574):1742-57. (Pubitemid 46755391)
43. Riethdorf S, Pantel K. Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann N Y Acad Sci. 2010;1210:66-77.
44. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002;360(9334):683-9. (Pubitemid 35232337)
45. Heppner GH, Miller FR. The cellular basis of tumor progression. Int Rev Cytol. 1998;177:1-56. (Pubitemid 128716720)
46. Strauss BS. Hypermutability and silent mutations in human carcinogenesis. Semin Cancer Biol. 1998;8(6):431-8. (Pubitemid 29151355)
47. Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg. 2012;255(2):357-62.
48. Yang L, Lang JC, Balasubramanian P, Jatana KR, Schuller D, Agrawal A, et al. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng. 2009;102(2):521-34.
49. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 2000;156(1):57-63. (Pubitemid 30644439)
50. Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med. 2006;12(3):130-9.
51. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991;338(8777):1227-9.
52. Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, et al. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol. 2011;38(3):755-60.
53. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302-9.
54. Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, Koutsilieris M. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis. 2004;21(6):495-505.
55. Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer. 2009;45(18):3189-97.
56. Lugo TG, Braun S, Cote RJ, Pantel K, Rusch V. Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol. 2003;21(13):2609-15. (Pubitemid 46606345)
57. Clawson GA, Kimchi E, Patrick SD, Xin P, Harouaka R, Zheng S, et al. Circulating tumor cells in melanoma patients. PLoS One. 2012;7(7):e41052.
58. Carlson JA, Ross JS, Slominski A, Linette G, Mysliborski J, Hill J, et al. Molecular diagnostics in melanoma. J Am Acad Dermatol. 2005;52(5):743-75 (quiz 75-8).
59. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235-9.
60. Palmieri G, Casula M, Sini MC, Ascierto PA, Cossu A. Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med. 2007;11(5):1052-68. (Pubitemid 350041638)
61. Mocellin S, Del Fiore P, Guarnieri L, Scalerta R, Foletto M, Chiarion V, et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer. 2004;111(5):741-5. (Pubitemid 39062897)
62. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20(8):2045-52. (Pubitemid 34408794)
63. Eton O, Rosenblum MG, Legha SS, Zhang W, Jo East M, Bedikian A, et al. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer. 2002;95(1):127-34. (Pubitemid 34743491)
64. Khayat D, Bernard-Marty C, Meric JB, Rixe O. Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol. 2002;20(10):2411-4. (Pubitemid 34525725)
65. Ma J, Lin JY, Alloo A, Wilson BJ, Schatton T, Zhan Q, et al. Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun. 2010;402(4):711-7.
66. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008;14(24):8019-26.
67. Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol. 2011;12(9):913-22.
68. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer. 2012;106(5):939-46.
69. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem. 2005;51(6):981-8. (Pubitemid 40740878)
70. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005;23(31):8057-64. (Pubitemid 46657408)
71. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366-77.
72. Kitago M, Koyanagi K, Nakamura T, Goto Y, Faries M, O'Day SJ, et al. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem. 2009;55(4):757-64.
73. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122(1):11-9.
74. Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, et al. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. J Invest Dermatol. 2013;133(5):1378-81.
75. Keilholz U, Goldin-Lang P, Bechrakis NE, Max N, Letsch A, Schmittel A, et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res. 2004;10(5):1605-12. (Pubitemid 38435549)
76. Mostert B, Sleijfer S, Foekens JA, Gratama JW. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev. 2009;35(5):463-74.